A second randomized controlled trial sponsored by JDRF also demonstrates superiority of automated insulin pump as first-in-line therapy for children with type 1 diabetes DUBLIN and BERLIN, Feb. 24, ...
The first study by Dr. Goran Petrovski, MD, PhD, of Sidra Medicine, randomly assigned adolescents using the MiniMed™ 780G system (n=34) into two groups, with some entering a fixed pre-set number of ...
New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy, March 9, 2024 ...
DUBLIN, June 11, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Marking of its MiniMed™ 780G system, a next ...
GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...
GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the ...
DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with ...
DUBLIN and SAN DIEGO, June 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the ...
Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results